{"schema_version":"secwatch.filing_event.v1","accession":"0001842952-25-000006","form_type":"8-K","ticker":"CNTX","cik":"0001842952","company_name":"Context Therapeutics Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.238392+00:00","generated_at":"2026-05-28T02:15:44.843042+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Context Therapeutics doses first patient in Phase 1 trial of CTIM-76 for CLDN6-positive cancers","bullets":["First patient dosed in Phase 1 open-label trial of CTIM-76 (CLDN6 x CD3 bispecific antibody).","Trial targets CLDN6-positive advanced/metastatic ovarian, endometrial, and testicular cancers.","Study expected to enroll up to 70 patients; initial data anticipated first half of 2026.","CEO Martin Lehr highlights the milestone as key pipeline advancement.","Company presented at SITC 2024 supporting first-in-human dose selection."],"urls":{"canonical":"https://secwatch.observer/filing/0001842952-25-000006","json":"https://secwatch.observer/filing/0001842952-25-000006.json","markdown":"https://secwatch.observer/filing/0001842952-25-000006.md","text":"https://secwatch.observer/filing/0001842952-25-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000006/0001842952-25-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1842952/000184295225000006/cntx-20250114.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:15:44.843042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}